This module discusses the scientific background and its application to the prevention and treatment of CVD with pharmacological therapies. The module aims to identify and evaluate best practice in the use of prophylactic drug therapies in the prevention of CVD. It explores the ass ociated clinical outcome data associated with best-practice and explores the current health care structure and policies that govern current practice. The mechanisms of dyslipidaemia, hypertension and diabetes and their treatment to reduce CVD are evaluated. An update on clinical guidelines and trial evidence in targeting CVD as well as the practical use of cardiovascular risk calculators are explored.